A Phase II Multicenter, Randomized, Placebo Controlled, Double Blinded Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients With Metastatic Colorectal Cancer
Phase of Trial: Phase II
Latest Information Update: 03 Aug 2017
At a glance
- Drugs KD 018 (Primary) ; Irinotecan
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- 28 Jul 2017 Status changed from recruiting to suspended.
- 13 Jun 2014 Planned number of patients changed from 54 to 165, Phase changed from IB/II to II and study included an additional placebo arm. Also, primary endpoints and study inclusion/exclusion criteria have been updated accordingly.
- 13 Jun 2014 Planned number of patients changed from 54 to 165 as reported by ClinicalTrials.gov.